These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38607993)

  • 1. Vonoprazan is Not Inferior to Proton Pump Inhibitors in Bismuth-containing Quadruple Therapy for Helicobacter pylori Eradication: A Meta-analysis of 10 Studies From East Asia.
    Cheng Y; Yang L; Xu S; Zhang C
    J Clin Gastroenterol; 2024 Apr; ():. PubMed ID: 38607993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy.
    Yang H; Zhang M; Ma G; Yang J; Wang K; Jiang S; Dong J; Han Y
    Helicobacter; 2024; 29(2):e13059. PubMed ID: 38443329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-CAB
    Jiang Y; Zhang R; Fang Y; Zhao R; Fu Y; Ren P; Zhan Q; Shao M
    Therap Adv Gastroenterol; 2024; 17():17562848241241223. PubMed ID: 38751605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
    Yang C; Li S; Huang T; Lin H; Jiang Z; He Y; Yuan J; An H
    J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
    Du RC; Hu YX; Ouyang Y; Ling LX; Xu JY; Sa R; Liu XS; Hong JB; Zhu Y; Lu NH; Hu Y
    Helicobacter; 2024; 29(1):e13039. PubMed ID: 38036941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of
    Zhang C; Zhang J; Cheng YJ
    Saudi J Gastroenterol; 2023; 29(2):88-94. PubMed ID: 36960527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Zhou BG; Jiang X; Ding YB; She Q; Li YY
    Helicobacter; 2024; 29(1):e13040. PubMed ID: 37983865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
    Chen S; Shen W; Liu Y; Dong Q; Shi Y
    Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
    Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
    Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
    Wang J; Li YY; Lin MJ; Liu J; Lin BS; Ding YM; Wan M; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
    J Dig Dis; 2023 Jan; 24(1):19-27. PubMed ID: 36960538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
    Lu L; Wang Y; Ye J; Han Y; Lou G; Li Y; Yan H; Du Q
    Helicobacter; 2023 Feb; 28(1):e12940. PubMed ID: 36458325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
    Qian HS; Li WJ; Dang YN; Li LR; Xu XB; Yuan L; Zhang WF; Yang Z; Gao X; Zhang M; Li X; Zhang GX
    Am J Gastroenterol; 2023 Apr; 118(4):627-634. PubMed ID: 36729890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose dual therapy
    Zhou BG; Mei YZ; Zhang M; Jiang X; Li YY; Ding YB
    Therap Adv Gastroenterol; 2023; 16():17562848221147756. PubMed ID: 36644129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
    Sun Y; Yue L; Hu W
    Eur J Clin Pharmacol; 2023 Feb; 79(2):279-288. PubMed ID: 36527456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis.
    Ding YM; Li YY; Liu J; Wang J; Wan M; Lin MJ; Lin BS; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
    Clin Exp Med; 2023 Aug; 23(4):1033-1043. PubMed ID: 36538198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
    Yan TL; Wang JH; He XJ; Zhu YB; Lu LJ; Wang YJ; Wang ZW; Gao JG; Xu CF; Ma H; Luan SM; Li L; Chen Y
    Am J Gastroenterol; 2024 Apr; 119(4):655-661. PubMed ID: 37975609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Dose Dual Therapy Versus Bismuth-Containing Quadruple Therapy for the Treatment of Helicobacter pylori Infection: A Systematic Review with Meta-Analysis.
    Yin Z; Li J; Huang W; Lei X; Xu D; Xu G; Li H; Zhang J
    Turk J Gastroenterol; 2022 Jun; 33(6):454-462. PubMed ID: 35786612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of
    Zhang M; Chen CY; Wang XT; Lyu B
    Zhonghua Nei Ke Za Zhi; 2017 May; 56(5):368-374. PubMed ID: 28460509
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial.
    Oh CK; Lim H; Seo SI; Lee SP; Bang CS; Shin WG; Kim JB; Jang HJ; Baik GH
    BMC Gastroenterol; 2023 Dec; 23(1):453. PubMed ID: 38129806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.